



28159 Avenue Stanford, Suite 220 Valencia, CA 91355  
T 833.462.8482 W [avitamedical.com](http://avitamedical.com)

30 January 2025

**LATE LODGEMENT OF APPENDIX 3Y**

Please find attached Appendix 3Y (Change of Director's Interest Notice) for Non-Executive Director Professor Suzanné Crowe (the "NED").

This Appendix reflects changes resulting from the purchase of equity on 9 December 2024 (with a settlement date of 11 December 2024).

Regarding the late lodgement of this Appendix, AVITA Medical ("the Company") confirms the following:

1. The Appendix 3Y is being lodged late due to an administrative oversight following purchase of the Company's equity by the NED. As soon as the oversight was identified, the document was lodged with ASX.
2. The Company and the NED are aware of their obligations under ASX Listing Rules 3.19A and 3.19B. The Company has an Insider Trading and Securities Dealing Policy in place which provides a process for the Company's employees, officers, and directors to notify the Company of intended trades in the Company's securities.
3. The Company considers that the late lodgement is an isolated incident and believes that its current practices are adequate to ensure compliance with the ASX Listing Rules.

Sincerely,

  
Nicole Linda Kelsey  
Chief Legal and Compliance Officer  
AVITA Medical

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: AVITA Medical, Inc. ("Company")</b>
<b>ARBN: 641 288 155</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Suzanne Crowe
<b>Date of last notice</b>	14 June 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	8 December 2024 (United States) / 9 December 2024 (Australia) - Common Stock

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held prior to change</b>	9,200 RSUs  20,560 CDIs  23,114 of common stock of the Company (which may be represented by CDIs).  2,550 Options expiring 23 Dec 2031 ex USD \$12.18.  5,395 Options expiring 13 Dec 2032 ex USD \$6.95.  2,646 Options expiring 7 June 2033 ex USD \$14.17.  3,943 Options expiring 6 June 2034, ex USD \$9.51
<b>Class</b>	Common Stock
<b>Number acquired</b>	2,430 Common Stock
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$4.11 (AUD)
<b>No. of securities held after change</b>	9,200 RSUs  22,990 CDIs  23,114 of common stock of the Company (which may be represented by CDIs).  2,550 Options expiring 23 Dec 2031 ex USD \$12.18.  5,395 Options expiring 13 Dec 2032 ex USD \$6.95.  2,646 Options expiring 7 June 2033 ex USD \$14.17.  3,943 Options expiring 6 June 2034, ex USD \$9.51
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On Market Trade

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

---

+ See chapter 19 for defined terms.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.